| BMC Complementary and Alternative Medicine | |
| Herbal formula Xian-Fang-Huo-Ming-Yin regulates differentiation of lymphocytes and production of pro-inflammatory cytokines in collagen-induced arthritis mice | |
| Research Article | |
| Dashuai Zhu1  Yongzhe Che1  Jingwei Zhou2  Mingwei Mu3  Bin Dong4  Limin Chai4  Bo Nie4  Aiming Wu4  Lingqun Zhu4  Yi Wei4  Lixia Lou4  Xue Li4  Jinyu Li5  Meng Chen6  | |
| [1] Department of Anatomy, School of Medicine, Nankai University, Tianjin, China;Department of Rheumatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China;Department of orthopedics Rheumatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China;Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Haiyuncang Hutong No.5,, Beijing, Dongcheng District, China;Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Haiyuncang Hutong No.5,, Beijing, Dongcheng District, China;Department of orthopedics Rheumatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China;School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing, China; | |
| 关键词: Xian-fang-huo-ming-Yin (XFHM); Lymphocyte; Pro-inflammatory cytokine; Nuclear factor κB (NF-κB); Janus-activated kinase-signal transducer and activator of transcription (JAK/STAT); Collagen-induced arthritis (CIA); | |
| DOI : 10.1186/s12906-016-1526-x | |
| received in 2016-04-25, accepted in 2016-12-07, 发布年份 2017 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
BackgroundXian-Fang-Huo-Ming-Yin (XFHM), a traditional herbal formula, has been used to treat sores and carbuncles for hundreds of years in Asia. Nowadays, its clinical effects in treatment of rheumatoid arthritis (RA) have been validated. In this study, we want to study its possible molecular mechanisms of regulating the differentiation of lymphocytes and production of pro-inflammatory cytokines in collagen-induced arthritis (CIA) mice for RA treatment.MethodsA high performance liquid chromatography-electrospray ionization/mass spectrometer (HPLC-ESI/MSn) system was used to analyze the constituents of XFHM granules. An arthritics mouse model was induced by collagen and leflunomide (LEF) was used as a positive control medicine. Pathological changes at the metatarsophalangeal joint were studied through Safranin O and immunohistochemical staining. The differentiation of T, B and NK cells was examined by flow cytometry and pro-inflammatory cytokines were assayed using an Inflammation Antibody Array assay. The expression of key molecules of the nuclear factor κB (NF-κB) and Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathways in spleen were studied by western-blot analysis.ResultsIn our study. 21 different dominant chemical constituents were identified in XFHM. Treatment with XFHM suppressed the pathological changes in arthrosis of CIA. Additionally, XFHM down-regulated the proliferation and differentiation of CD3+ T cells and CD3−CD19+ B cells significantly. However, XFHM had no significant effect on CD3−NK1.1+ NK cells. Further study showed that the production of pro-inflammatory cytokines had been suppressed by inhibiting the activation of NF-κB and JAK/STAT signaling.ConclusionsXFHM can regulate and maintain the immunologic balance of lymphocytic immunity and inhibit the production of pro-inflammatory cytokines, thus suppressing the pathological changes of RA. Therefore, XFHM may be used as an application of traditional medicine against RA in modern complementary and alternative therapeutics.
【 授权许可】
CC BY
© The Author(s). 2017
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202311090843383ZK.pdf | 4649KB |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]
- [42]
- [43]
- [44]
- [45]
- [46]
- [47]
- [48]
- [49]
- [50]
- [51]
- [52]
- [53]
- [54]
- [55]
- [56]
- [57]
- [58]
- [59]
PDF